Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2020 Earnings Presentation
21 slides from Arcticzymes Technologies Asa's earnings presentation, Apr 23, 2020
Slide 1: Q1 2020 Presentation
Q1 2020 Presentation 23.04.2020, Oslo/Tromsø
Slide 2: Agenda
Agenda • Q1 Highlights • ArcticZymes Update • BetaGlucans Update • Response to Coronavirus • Q1 Financials • Corporate Strategy 2
Slide 3: Q1 Highlights
Q1 Highlights
Slide 4: Highlights Q1 2020
Highlights Q1 2020 Sales & Gross profit • Positive EBITDA with NOK 13.8 million (-3.9) 40 000 Sales Gross profit 35 000 • ArcticZymes had Q1 2020 sales of NOK 18.5 million (7.9), growing by 135% 30 000 • ArcticZymes growth driven by strong sales in the 25 000 therapeutic segment and upsides relating
Slide 5: ArcticZymes
ArcticZymes ‘e—8,. BIOTEC +See PHARMACON
Slide 6: ArcticZymes Update
ArcticZymes Update Commercial achievements • Best quarterly financial performance • Key attributors to growth ✓ Salt Active Nuclease (SAN) product portfolio – starting to receive and expedite individual large bulk orders >1 MNOK ✓ Upsides related to use of Cod UNG and DNase in COVID-19 diagnostic te
Slide 7: ArcticZymes Update: Innovations
ArcticZymes Update Innovations • Launched a new formulation of dsDNase • Filed a new patent application related to one of our novel ligases in the pipeline ✓ Offers desirable features specifically requested by our customers which are not present in other commercially available ligases today ✓ Launch
Slide 8: ArcticZymes M&A Status
ArcticZymes M&A Status Status • Initiated acquisition negotiations with a European based enzyme company • Unable to reach a fair price to make the transaction worthwhile without excessively overpaying • Both parties mutually agreed to terminate the negotiations in good faith Next Steps • Advancing n
Slide 9: BetaGlucans
BetaGlucans Animal Health, Consumer Health, SBG® Adjuvant & Woulgan®
Slide 10: Biotec BetaGlucans Update
Biotec BetaGlucans Update Animal Health Consumer Health SBG® (Adjuvant) Woulgan® • Achieved growth in sales of • Achieved growth in sales of • Secured 2020 purchasing • Sales to existing customers M-Glucan® M-Gard® commitments to support deliver to expectation continuation of clinical trials • Drive
Slide 11: Coronavirus Pandemic
Coronavirus Pandemic Company’s Response
Slide 12: Response to Coronavirus Pandemic
Response to Coronavirus Pandemic Strict hygeine measures First Priority Back up More frequent Protect resources & employees, increased warehouse production stocking supply chain & capacity customers Home office for non- operational staff 12
Slide 13: Q1 Financials
Q1 Financials “east BIOTEC “so ret” PHARMACON
Slide 14: Cash Flow Positive for 3rd Quarter in a Row
Cash Flow Positive for 3rd Quarter in a Row Net cash position First quarter changes in cash of 4.4 MNOK: Amounts in NOK 1.000' 40 000 35 000 • 24.7 (13.2) MNOK in short-term 30 000 receivables 25 000 • 17.3 (10.4) MNOK in short-term payables 20 000 • Cash Flow from operations 5.9 MNOK 35 667 (-2.6 M
Slide 15: Growth in All Areas
Growth in All Areas Biotec revenues per segment Amounts in NOK 1.000' 20 000 Animal,Consumer Health & Adjuvant Segment Q1 Sales ArcticZymes 15 000 Woulgan ArcticZymes MNOK 18.5 (7.9) Animal, Consumer Health MNOK 14.6 (5.7) & Adjuvant 10 000 Woulgan® MNOK 1.2 (1.2) 5 000 Group MNOK 34.3 (14.8) 0 Q1 2
Slide 16: EBITDA All Time High…..Again
EBITDA All Time High…..Again Operating Expenses EBITDA Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Personell expenses 16 000 Amounts in NOK 1.000' 14 000 Property, plant and equipment 12 000 IT 10 000 8 000 External services 6 000 Marketing and sales 4 000 2 000 License, patent and trademark 0 Other ope
Slide 17: ArcticZymes Performance
ArcticZymes Performance Enzymes Q1 YTD • Sales up by 10.6 MNOK or 135% compared to 2020 2019 2020 2019 same quarter last year (Amounts in NOK 1.000) Sales revenues 18 475 7 869 18 475 7 869 Operating expenses -9 182 -8 885 -9 182 -8 885 EBITDA 10 462 -377 10 462 -377 • Operating expenses increased d
Slide 18: BetaGlucans Performance
BetaGlucans Performance BetaGlucans Q1 YTD • Sales within Animal Health accounts for 2020 2019 2020 2019 (Amounts in NOK 1.000) almost 10 MNOK of sales revenues Sales revenues 15 798 6 947 15 798 6 947 Gross profit 7 654 4 152 7 654 4 152 Operating expenses -3 518 -6 521 -3 518 -6 521 • Gross profit
Slide 19: Corporate Strategy
Corporate Strategy # Se Fa JACON
Slide 20: Corporate Strategy
Corporate Strategy • Corporate Rebranding ✓ Timely to refresh Biotec’s brand position and external facing image ✓ Propose to rebrand Biotec Pharmacon under the new name of ArcticZymes Technologies ✓ Resonates with the company´s core business, its corporate strategy, and ArcticZymes’ strong brand pos
Slide 21: THANK YOU
THANK YOU Reminder AGM 14th May in Tromsø 21
ArcticZymes Technologies — Q1 2020 Earnings Presentation on 6ix